“The positive data and mechanistic analysis presented in the first quarter build on the positive preclinical and clinical data package for TPST-1120, further confirming and reinforcing our excitement about the potential of TPST-1120 in liver and kidney cancers, as well as other indications, and our confidence in the program as it moves closer to a pivotal Phase 3 study in first-line HCC,” said Stephen Brady, president and chief executive officer of Tempest.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST:
- Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
- Is TPST a Buy, Before Earnings?
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Largest borrow rate increases among liquid names
- Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting